@article{Nutt:2022:10.1016/j.neuropharm.2022.109257,
author = {Nutt, D and Spriggs, M and Erritzoe, D},
doi = {10.1016/j.neuropharm.2022.109257},
journal = {Neuropharmacology},
title = {Psychedelics therapeutics: What we know, what we think, and what we need to research.},
url = {http://dx.doi.org/10.1016/j.neuropharm.2022.109257},
year = {2022}
}

Download

TY  - JOUR
AB  - Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only does it offer a radical new approach to treatment where mainstream approaches have proven ineffective, but the growing evidence for transdiagnostic efficacy is eliciting a re-think of current diagnostic and symptom-specific approaches to psychiatry. This excitement has led to a massive investment in this field with many tens of new pharmaceutical companies being set up to research the effects of known psychedelics and develop new patentable molecules. Whilst this enthusiasm is to be welcomed, it is important that new research is properly grounded in established facts and reflects current knowledge. In this commentary we lay out the knowledge framework that should be taken into account by all researchers innovation this field.
AU  - Nutt,D
AU  - Spriggs,M
AU  - Erritzoe,D
DO  - 10.1016/j.neuropharm.2022.109257
PY  - 2022///
TI  - Psychedelics therapeutics: What we know, what we think, and what we need to research.
T2  - Neuropharmacology
UR  - http://dx.doi.org/10.1016/j.neuropharm.2022.109257
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36179919
ER  - 

Download